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Pulmonary hypertension due to left heart disease (PH-LHD) is the most common type
of pulmonary hypertension, although an accurate prevalence is challenging. PH-LHD
includes PH due to systolic or diastolic left ventricular dysfunction, mitral or aortic valve
disease and congenital left heart disease. In recent years a new and distinct phenotype of
“combined post-capillary and pre-capillary PH,” based on diastolic pulmonary gradient
and pulmonary vascular resistance, has been recognized. The roles of right ventricular
dysfunction and pulmonary vascular compliance in PH-LHD have also been elucidated
recently and they appear to have significant clinical implications. Echocardiography
continues to play a seminal role in diagnosis of PH-LHD and heart failure with preserved
LV ejection fraction, as it can identify valve disease and help to distinguish PH-LHD
from pre-capillary PH. Right, and occasionally left heart catheterization, remains the
gold-standard for diagnosis and phenotyping of PH-LHD, although Cardiac Magnetic
Resonance Imaging is emerging as a useful alternative tool in non-invasive diagnostic
and prognostic assessment of PH-LHD. In this review, the latest evidence for more recent
advances will be discussed, including the role of fluid challenge and exercise during
cardiac catheterization to unravel occult post-capillary and the role of vasoreactivity
testing. The use of many or all of these diagnostic techniques will undoubtedly provide key
information about sub-groups of patients with PH-LHD that might benefit from medical
therapy previously considered to be only suitable for pulmonary arterial hypertension.
Keywords: pulmonary hypertension, left heart disease, heart failure with preserved ejection fraction, left
ventricular diastolic dysfunction, right heart catheterization
INTRODUCTION
Pulmonary hypertension due to left heart disease (PH-LHD) is the most common type of
pulmonary hypertension (PH). The prevalence of PH in patients with heart failure varies
significantly with diagnostic criteria from 25 to 83% (1–4). PH-LHD is defined by post-capillary
hemodynamics at right heart catheterization (RHC); that is a mean pulmonary arterial pressure
≥25 mmHg and a mean pulmonary arterial wedge pressure (PAWP) > 15 mmHg. PAWP
is a surrogate marker of left atrial pressure (LAP). An elevated LAP causing PH can
occur in systolic and/or diastolic left ventricular (LV) dysfunction and in left-sided valvular
disease. In the most recent clinical classification of PH (5) two additional etiologies of
PH-LHD have been recognized: PH due to congenital or acquired left ventricular outflow tract
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TABLE 1 | Definitions.
Pre-capillary PH Mean PAP ≥ 25 mmHg, mean PAWP
≤15 mmHg
Isolated post-capillary PH Mean PAP ≥ 25 mmHg, mean PAWP
>15 mmHg, DPG < 7 mmHg and/or
PVR ≤ 3 Wood units
Combined pre-capillary and
post-capillary PH
Mean PAP ≥ 25 mmHg, mean PAWP
>15 mmHg, DPG ≥ 7 mmHg and/or
PVR > 3 Wood units
PAP, pulmonary artery pressure; PAWP, pulmonary artery wedge pressure; DPG, diastolic
pressure gradient; PVR, pulmonary vascular resistance. Modified from 2015 ESC/ERS
Pulmonary Hypertension Guidelines (5).
obstruction and pulmonary vein stenosis. In the same guidelines,
a new PH phenotype of “combined pre-capillary and post-
capillary PH” (Cpc-PH) has been introduced on the grounds
of a diastolic pressure gradient (DPG)-the difference between
diastolic pulmonary arterial pressure and mean PAWP-equal
or higher than 7 mmHg (Table 1). This new term came to
replace the older “PH out of proportion to LHD.” Although,
pathophysiology of Cpc-PH is not entirely clear, a chronic
elevation of LAP due to longstanding LHD is believed to
cause a profound pulmonary artery remodeling and pulmonary
vascular resistance (PVR) rise, which is not usually found in
isolated post-capillary PH. Patients with Cpc-PH seem to be
in the middle of a spectrum of which pre-capillary PH and
isolated post-capillary PH are the two extremes, regarding their
clinical and echocardiographic characteristics (6).The prevalence
of Cpc-PH amongst patients with systolic and diastolic heart
failure is believed to be within 12 and 14% (7). An adequate
understanding of pathophysiology along with an accurate
diagnosis and differentiation of PH-LHD from pre-capillary PH,
such as pulmonary arterial hypertension (PAH) and chronic
thromboembolic PH (CTEPH), are of paramount importance to
select the appropriate treatment for the patient.
PATHOPHYSIOLOGY
The pathophysiological hallmark of PH-LHD is elevated LAP. LV
systolic and diastolic dysfunction as well as aortic and/or mitral
valve stenosis and/or regurgitation can raise left ventricular
filling pressure and subsequently LAP over a period of time.
LAP can then be transmitted backwards via pulmonary veins
to the pulmonary vasculature leading to pulmonary arterial
intimal thickening and medial hypertrophy and PH (Figure 1).
Compliance in the pulmonary vasculature, unlike in the systemic
circulation, is more evenly distributed across the pulmonary bed
and the distal vessels are responsible for most of it (8). Hence,
compliance is mostly determined by PVR. The relationship
between PVR and compliance is an inverse hyperbolic one.
“Passive” left-sided elevated pressures shift the hyperbole
leftwards leading to an additional decline of compliance for a
given PVR and thus enhanced pulmonary wave reflections which
return during ventricular systole and increase the systolic (but
not the diastolic) pulmonary artery pressure (9). In a recent
study, pulmonary arterial compliance (or capacitance) defined
as the ratio of stroke volume to pulmonary pulse pressure
was the best predictor of mortality in PH-LHD associated with
heart failure with preserved left ventricular ejection fraction
(HFpEF) (10).
The Right Ventricle (RV)
The first compensatory mechanism of the RV to the elevated
pulmonary pressure is hypertrophy. Thus, the RV can adapt with
a 4- to 5-fold increase inmyocardial contractility, a process which
is described pathophysiologically as right ventricular-pulmonary
artery (RV-PA) “coupling.” In the next progressive stage the RV
starts dilating, wall stress according to LaPlace’s law increases,
imbalance between oxygen demand and supply and RV ischemia
occurs, contractility declines, the RV fails to maintain cardiac
output and inevitably “uncoupling” and decompensation begins.
The development of tricuspid (TR) and pulmonary regurgitation
due to annular dilatation leads to RV volume overloading and
decreases stroke volume even further. RV-PA coupling has been
estimated by echocardiography as the ratio of tricuspid annular
plane systolic excursion (TAPSE) to pulmonary artery systolic
pressure (PASP) and a cut-off limit <0.36 has been shown to
have prognostic value (11). Coupling has also been estimated by a
hybrid method combining RHC and cardiac magnetic resonance
(CMR) as the ratio of pulmonary artery effective elastance, which
is a measure of arterial load, to the maximum end-systolic RV
elastance, which is an index of contractility (12).
Up until recently the impact of PH-LHD on RV function had
been underestimated. In recent years, however, its significance
and prognostic value has been highlighted. RV systolic
dysfunction assessed by echocardiography has been found in at
least 1/5 of patients with HFpEF and potentially up to 30–50%
(13). In addition, a decrease of TAPSE by 5mm was associated
with a 26% mortality rise (13), while in another study a decrease
of RV fractional area change by 7% with a 2.2-fold increase of
all-cause mortality after adjustment for pulmonary pressures in
patients with HFpEF (14).
Ventricular Interdependence and
Comorbidities
Other parameters such as ventricular interdependence may
contribute to decreased cardiac output and heart failure. As
RV pressure increases and interventricular dyssynchrony is
established, the interventricular septum bows toward the LV
moving “paradoxically” and leading to a decrease of LV diastolic
filling and a further drop of stroke volume. In addition,
atrial fibrillation, coronary artery disease via right coronary
or circumflex artery stenosis leading to reduced RV oxygen
supply, chronic obstructive pulmonary disease, obstructive sleep
apnea, diabetes, and obesity, all comorbidities frequently seen
in patients with LHD may increase pulmonary pressures and
further compromise RV function.
The Role of DPG
DPG has been considered to be a more accurate indicator of
pulmonary vascular remodeling in LHD than transpulmonary
gradient (the difference betweenmean pulmonary artery pressure
and mean PAWP [TPG]), as it is theoretically not influenced
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FIGURE 1 | Pathophysiological mechanisms of pulmonary hypertension due to left heart disease.
by the variability of cardiac output or the impact of LAP
on pulmonary vascular compliance. In a retrospective large
study in patients with PH-LHD an elevated DPG ≥ 7 mmHg
was correlated with worse median survival compared with a
DPG < 7 mmHg and a high TPG > 12 mmHg (15). In the
same study, in a small number of patients high DPG was
also correlated with greater pathological pulmonary vascular
remodeling compared to patients with high TPG but normal
DPG. Two further studies, retrospective as well, in patients
who had undergone orthotopic heart transplantation and in
patients with unexplained cardiomyopathy did not confirm the
prognostic value of DPG (16, 17). In a more recent study
the risk of death in Cpc-PH and isolated post-capillary PH
after adjustment of relevant covariates was similar, however
the researchers identified 75 common exonic single-nucleotide
polymorphisms between Cpc-PH and pre-capillary PH in
pathways pertinent with cell structure, extracellular matrix and
immune function (6).
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DIAGNOSIS
Risk Factors, Clinical Symptoms, and
Signs
Features of metabolic syndrome such as obesity, systemic
hypertension, diabetes and dyslipidemia, are more prevalent in
patients with PH-LHD than PAH. Researchers have shown that
two or more of these features were present in 94.1% of PH-
LHD patients vs. only 34.3% of PAH (18). The findings were
confirmed in another study, which showed that older age, the
presence of systemic hypertension and coronary artery disease
are more frequent in PH-LHD and can best differentiate from
PAH along with other echocardiographic and hemodynamic
parameters (19). In the same study there was a similarly high
female predominance in the PH-LHD and PAH groups but more
pronounced than in the HFpEF without PH group. In addition to
these risk factors, the prevalence of permanent atrial fibrillation
in PH-LHD seems to be significantly higher than in patients with
PAH and risk factors for LHD (20).
The symptoms and clinical signs of patients with PH-LHD
are these of heart failure. Exertional dyspnea, orthopnea, and/or
paroxysmal nocturnal dyspnea, anginal chest pain typically on
exertion, palpitations, dry cough, pre-syncope and/or syncope,
hepatomegaly, ascites, elevated jugular venous pressure, and
peripheral edema are the most common ones. Right ventricular
heave, a loud pulmonary component of the second heart sound
and a pansystolic murmur of tricuspid regurgitation may also
be present. In a retrospective study which compared patients
with PAH with or without cardiovascular comorbidities to PH-
LHD, patients with PH-LHD were more likely to have peripheral
edema, whilst there was a trend toward a worse functional class
after adjustment for age but no difference in 6-min walking test
distance (20). Patients with PH-LHD usually have normal resting
oxygen saturations with a possible drop on exercise, unless if they
also have respiratory comorbidity or a right-to-left shunt.
Chest X-Ray, ECG, and Pulmonary
Function Test
The chest X-ray may show signs of cardiomegaly and enlarged
pulmonary artery branches. Pleural effusions may be seen
more frequently in PH-LHD than PAH, although they are not
uncommon in severe PAH as well (21).
Left QRS axis deviation, atrial fibrillation and signs of left
ventricular hypertrophy are more likely on ECG in PH-LHD
than in pre-capillary PH, whereas right axis, sinus rhythm, R
wave dominant in lead V1, ST-T segment depression, and T-
wave inversion in the right precordial and inferior leads are more
frequently seen in pre-capillary PH. Right bundle branch block
does not appear to differentiate the two conditions (20, 22). These
ECG findings have been recently incorporated in predictive score
models to discriminate non-invasively between PH-LHD and
PAH (23, 24).
It is well-known that pulmonary alveolar diffusion is impaired
in patients with congestive heart failure. Gas transfer factor for
carbon monoxide (TLco) is reduced in this population compared
to controls (25). In addition, TLco and end-tidal CO2 have been
found to be lower in PAHpatients compared to PH-LHD (26, 27).
In the ASPIRE registry, mean TLco in the PAH group was 55 vs.
62% predicted in the PH-LHD one (26).
Natriuretic Peptides
Brain natriuretic peptide (BNP) and its N-terminal fragment NT-
proBNP can both be elevated in heart failure with reduced LV
ejection fraction and HFpEF. They can be secreted from the
cardiomyocytes of both ventricles due to stretching from volume
overload. The upper limit of normal for BNP is 35 pg/mL and
for NT-proBNP 125 pg/mL (28). Natriuretic peptides may be
elevated in elderly people, atrial fibrillation and renal impairment
without heart failure. They can also be disproportionally low in
obese patients. In addition, they cannot differentiate between
pre-capillary PH and PH-LHD as they may be raised in both
conditions. Their role in patients’ follow-up, assessment of
response to treatment and detection of progression of the
underlying disease as well as their prognostic role can be very
important.
Echocardiography
Echocardiography plays a seminal role in the detection of signs of
PH-LHD. It can diagnose LV systolic and diastolic dysfunction,
aortic and mitral valve disease, LV outflow tract obstruction,
restrictive and hypertrophic cardiomyopathy and constrictive
pericarditis. In all these conditions, LV diastolic dysfunction
usually occurs and may lead to PH-LHD. The estimation of
PASP, which raises the suspicion of PH when elevated, derives
from applying continuous Doppler and the modified Bernoulli
equation: 4 x peak TR velocity (TRV)2 + estimated right atrial
pressure. Right atrial pressure can be estimated from the size and
collapsibility during respiration/sniff of the inferior vena cava
on the subcostal view (29). According to the current ESC/ERS
guidelines a threshold of peak TRV higher than 2.8 m/s is
considered suspicious of PH with or without the presence of
other echocardiographic signs of PH and risk factors for PH
(5). However, peak TRV is angle and flow-dependent and it can
frequently be under- or overestimated (30). Peak TRV should
be measured from several different acoustic windows and views,
while in atrial fibrillation an average of measurements from the
view with the highest velocities should be taken and only a well-
defined, spade-shaped, dense spectral profile should bemeasured.
In cases with no or trivial TR when TRV cannot accurately be
estimated, mean pulmonary artery pressure can be calculated
instead from the peak velocity of a pulmonary regurgitant jet at
the beginning of diastole or from the acceleration time (time from
onset to peak) of the forward flow at the right ventricular outflow
tract (29).
Diagnosing LV diastolic dysfunction with echocardiography
sometimes can be challenging. Four parameters have been
recently included in an algorithm to determine diastolic
dysfunction: an average (of septal and lateral) E/e’ > 14, a septal
e’ < 7 cm/s or lateral <10 cm/s, a TRV > 2.8 m/s and a left
atrial volume index >34 ml/m2. If <50% of these parameters
are present, diastolic function is normal, if >50%, there is
diastolic dysfunction and when exactly 50%, diastolic function
is indeterminate (31). Other echocardiographic signs such as
mitral “L” velocity >20 cm/s (ongoing LV filling in mid-diastole
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due to markedly delayed LV relaxation), mitral inflow E/A wave
velocity ratio and E wave deceleration time, as well as a higher
diastolic wave velocity than the systolic one in the pulmonary
vein Pulsed Doppler profile may also be useful (31). Unlike PH-
LHD, significant LV diastolic dysfunction in PAH is very unlikely.
In a small study, 88% of PAH patients demonstrated grade I
(mild) diastolic dysfunction and 10% normal diastolic function
(32).
Left atrial dilatation is considered to be one of the most useful
indicators of LHD. However, in the presence of atrial fibrillation
may not always represent elevated LAP. In atrial fibrillation, an
average E/e’ ≥11 instead of 14 should be used as a marker of
diastolic dysfunction (31). Researchers in the past have described
conditions such as severe mitral regurgitation with a dilated left
atrium but normal LAP. Left atrial compliance seems to play
a pivotal role in these cases (33). The absence of mid-systolic
“notching” in the right ventricular outflow tract Pulsed Doppler
envelope has also been shown to be highly predictive of a PVR <
3Wood units and a PAWP>15mmHg (34). On the other hand, a
PASP> 70 mmHg is more likely to represent PAH than PH-LHD
(35). The severity of TR cannot differentiate between PH-LHD
and PAH. In a prospective cohort of patients with PAH and PH-
LHD, 45% had mild, 34% moderate, and 21% severe TR. The
mechanisms causing TRwere annular dilatation, RV remodeling-
tethering and inadequate tricuspid valve leaflet area (36). Finally,
a RV end-diastolic diameter to LV end-diastolic diameter ratio
(measured in the 4-chamber apical view at the tips of the
atrioventricular valves)<1 and the absence of pericardial effusion
seem to be more likely in PH-LHD than PAH (20). Table 2
summarizes the distinct echocardiographic characteristics in pre-
capillary PH and PH-LHD. An echocardiographic score based
on LA dimension, mid-systolic notching and E/e’ to differentiate
between PH-LHD and PAH has been proposed (37). More
recently another echocardiographic score, which seems to be
useful in discriminating between isolated and Cpc-PH as well, has
been published (38).
CMR
CMR may play an important role in making diagnosis and
identifying prognosis of PH in general and PH-LHD in
particular. Especially in cases where visualization or accuracy of
measurements is limited, CMR should be strongly considered.
CMR remains the gold standard imaging modality for RV
assessment (39). Beyond RV size and function, CMR can quantify
the curvature of interventricular septum and more recently
pulmonary arterial stiffness, which may detect early stages
of pulmonary vascular remodeling (40, 41). In the ASPIRE
registry, patients with PH-LHD had lower RV mass, a better-
preserved cardiac function and less gadolinium hinge-point
enhancement compared to pre-capillary PH (42). In addition,
CMR is an excellent tool for myocardial tissue characterization
and with the use of late gadolinium enhancement it can diagnose
infiltrative cardiomyopathies e.g., amyloidosis, hypertrophic
cardiomyopathy, as well as systolic and diastolic LV dysfunction.
CMR can also play a significant role in diagnosis of congenital
heart diseases, which may be related to both PAH and PH-LHD.
TABLE 2 | Echocardiographic features likely to be present in pre- and
post-capillary pulmonary hypertension.
Pre-capillary PH PH-LHD
Normal sized or small LV cavity Normal sized or dilated LV cavity
No LV hypertrophy LV hypertrophy
Preserved LVEF Variable LVEF
Normal sized or small left atrium Dilated left atrium
Grade I LV diastolic dysfunction
or normal LV diastolic function
≥ Grade II LV diastolic
dysfunction
Presence of mid-systolic
notching
Absence of mid-systolic notching
RV/LV ratio > 1 RV/LV ratio < 1
PASP > 70 mmHg Typically PASP < 70 mmHg
Pericardial effusion No pericardial effusion
No mitral and/or aortic valve
disease
Mitral and/or aortic valve disease
PH-LHD, pulmonary hypertension due to left heart disease; LV, left ventricle; LVEF, left
ventricular ejection fraction; RV/LV ratio, right ventricular to left ventricular end-diastolic
diameter ratio; PASP, pulmonary artery systolic pressure. Modified from Roberts JD and
Forfia PR. Pulm Circ. 2011;1:160-181.
Predictive Non-invasive Score Models
Over the last few years, score models to assess the pre-
RHC probability of PH-LHD have been created aspiring to
avoid potentially unnecessary catheterizations. Bonderman et al.
proposed a model based on RV strain on ECG and BNP (23).
Jacobs et al. suggested a risk model including history of LHD, the
sum of S deflection in V1 and R deflection in V6 on the ECG,
left atrial dilatation and left valve disease worse than mild on
echocardiogram (24). Finally, Richter et al. suggested a prediction
score for elevated PAWP based on age >68 years, BMI > 30
kg/m2, absence of RV enlargement and presence of left atrial
dilatation on echocardiography (43).
RHC-Fluid
Challenge-Exercise-Vasoreactivity Testing
The gold standard method for the diagnosis of PH-LHD remains
RHC. All pulmonary pressures should be measured at end-
expiration with the patient breathing spontaneously. The mean
PAWP has been better correlated with mean LAP than the LV
end-diastolic pressure (LVEDP) in patients with LV disease,
except for very high PAWP over 25 mmHg (44, 45). However,
a LVEDP > 15 mmHg on left heart catheterization can be used
to define PH-LHD, when an accurate PAWP is not feasible
(e.g., in chronic thromboembolic disease). An accurate PAWP
may be challenging to obtain. A waveform consistent with atrial
waveform, a PAWP ≤ diastolic pulmonary arterial pressure,
blood easily aspirated and highly oxygenated in the wedge
position and the placement of the tip of the catheter inWest zone
3 (at the lung base, where pulmonary artery and venous pressure
exceeds pulmonary alveolar pressure, which represents lung areas
with the greatest blood flow rates), below left atrial level, can
eliminate technical difficulties. Mitral regurgitation may cause
large “v” waves that can be mistakenly interpreted as an elevated
PAWP. This can be accounted for by reading the PAWP at the
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time of the “a” wave. Patients with PH-LHD tend to have a higher
mean right atrial pressure, cardiac output and right ventricular
end-diastolic pressure, as well as lower PVR compared with PAH
(19, 20).
Patients with clinical and echocardiographic features
suggestive of PH-LHD may sometimes have pre-capillary PH,
especially if they have been previously heavily diuresed. Fluid
challenge, which is the rapid intravenous administration of a high
volume of normal saline, is believed to be helpful to unpick cases
of occult PH-LHD with resting pre-capillary hemodynamics
and unmask LV diastolic dysfunction. The current ESC/ERS
PH guidelines do not recommend fluid loading at RHC due to
lack of standardization as well as the theoretical risk of a rapid
significant PAWP elevation to result in pulmonary edema. Three
studies with fluid challenge in PH patients have been conducted
since the publication of these guidelines though. In the first
one, the infusion of 500mL of saline within 5–10min led to the
reclassification of 22.2% of patients as occult PH-LHD (defined
as a mean PAWP > 15 mmHg), while in another small study in
patients with systemic sclerosis a similar percentage of patients
with pre-capillary baseline hemodynamics were found to have a
LVEDP > 15 mmHg post-infusion of 500mL within 5–10min
(46, 47). In the most recent one, rapid infusion of saline at a
rate of 7 mL/kg reclassified 8% of patients with no PH and 6%
of patients with pre-capillary PH at baseline. A cut-off limit of
PAWP ≥ 18 mmHg was used in the latter study (48). In all three
studies, fluid loading was safe. Of note, even in healthy subjects
a rapid fluid infusion will lead to a PAWP > 15 mmHg in a
percentage >60%, however with a larger than 500mL volume of
saline (49). Likewise, exercise during RHC may unmask diastolic
dysfunction in patients with suspected HFpEF and a baseline
PAWP < 15 mmHg. Exercise can be performed on a supine
or upright bike (the latter would be feasible when the RHC is
done from the neck or the arm) or with leg lifting. In normal
subjects and athletes, an increase of PAWP up to 25 mmHg in
a broadly linear fashion with cardiac output has been shown
(50). However, significant increases of PAWP at a cardiac output
<10 L/min is uncommon in normal individuals. Exercise during
RHC seems to be particularly helpful in obese patients with a
borderline, between 12 and 15 mmHg, PAWP (51).
According to the ESC/ERS guidelines vasoreactivity testing
is only recommended in patients with suspected idiopathic,
familial, or drug-induced PAH (5). In the context of PH-LHD
vasodilator challenge can be used in the evaluation of patients
for listing for cardiac transplantation, especially those with a
TPG > 12–15 mmHg and/or PVR > 3 Wood units. The
preferable vasodilator agent is inhaled nitric oxide. An increase
of PAWP post-nitric oxide may be seen but pulmonary edema is
very rare.
Treatment
PAH targeted therapies act on three distinct pathophysiological
pathways. The first one is the nitric oxide-soluble guanylate
cyclase (sGC)-cGMP pathway which includes drugs like
phosphodiesterase type 5 inhibitors (Sildenafil, Tadalafil) and
stimulators of cGC like Riociguat. The second one is the
endothelin-1 pathway with drugs like endothelin receptor
antagonists (Bosentan, Ambrisentan, and Macitentan) and the
third is the prostacyclin pathway with prostacyclin analogs
(Epoprostenol, Treprostinil, Iloprost) and an oral selective
IP prostacyclin-receptor agonist (Selexipag). These drugs have
proven to be efficacious in PAH and CTEPH patients in several
randomized, controlled, double-blind trials. On the other hand,
trials of the same drugs in patients with PH-LHD have not
shown any benefit and some of them have also been related with
increased mortality (52–54). In the recent SIOVAC trial (55),
where Sildenafil was tested vs. placebo in patients with post-
capillary PH and history of correction of valvular heart disease,
median PVR in the Sildenafil group was 3.4 Wood units, TPG
16 mmHg, but DPG only 2 mmHg. Of note, the study did not
meet its primary end-point. Further trials need to be conducted
in patients with Cpc-PH hemodynamics to answer the question
about a possible efficacy of pulmonary vasodilator drugs in this
specific PH phenotype.
CONCLUSIONS
Up to now, no pulmonary vasodilator treatment has proven to
be efficacious in PH-LHD. Some of the PAH drugs have even
been detrimental when given in patients with LHD. Hence, it is
apparent that the accurate identification of the major driver of
PH in each patient is essential. In clinical practice the diagnosis
and phenotyping of PH cannot be based on a single test, even
if that test is the RHC, but rather on a combination of clinical
data, imaging and hemodynamics. A better understanding of
pathophysiology and further clinical trials are required to clarify
whether Cpc-PH is a distinct clinical entity or part of a spectrum
of PH phenotypes and identify potential treatments for the
future.
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